Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
idecabtagene vicleucel + iberdomide
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous (idecabtagene Vicleucel), Oral (iberdomide)
01
Overview
This is a **combination therapy** consisting of **idecabtagene vicleucel**, a chimeric antigen receptor T-cell (CAR-T) product targeting B-cell maturation antigen (BCMA) on multiple myeloma cells, and **iberdomide**, a small molecule cereblon E3 ligase modulator (CELMoD). Idecabtagene vicleucel is designed to recognize and eliminate BCMA-expressing malignant plasma cells, resulting in direct antitumor activity. Iberdomide modulates the CRL4-CRBN E3 ubiquitin ligase complex, promoting proteasomal degradation of transcription factors like Ikaros (IKZF1) and Aiolos (IKZF3), which reduces their levels and enhances T-cell and immune activation as well as inhibits multiple myeloma cell proliferation. This combination is being studied as maintenance therapy following idecabtagene vicleucel CAR-T therapy in **relapsed or refractory multiple myeloma**[1][3][5][6].
- Brand names
- Abecma (idecabtagene vicleucel)
- Other names
- ide-cel (idecabtagene vicleucel)idecabtagene vicleucel (Abecma)iberdomida
02
Targets
IKZF1 (Ikaros family zinc finger protein 1)CRBN (Cereblon)IKZF3 (Zinc finger protein Aiolos)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on idecabtagene vicleucel + iberdomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on idecabtagene vicleucel + iberdomide.